An FDA advisory committee has voted to recommend adding six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—to a list of ingredients approved for use by specialty pharmacies in custom medications. The decision, which came after a two-day hearing, reflects a shift towards meeting public demand for these compounds despite warnings from FDA scientists about the lack of robust clinical trial data and potential health risks. The committee’s vote is non-binding and requires FDA approval, which may be expedited by the support of Health and Human Services Secretary Robert F. Kennedy Jr. The panel declined to add emideltide to the list due to insufficient evidence of its efficacy. This decision highlights a divide between the committee’s members, many of whom operate clinics using peptides, and the FDA’s scientific staff.
Why It Matters
The addition of these peptides could significantly change how patients access these treatments, as licensed compounding pharmacies would be able to legally obtain and prepare them with a doctor’s prescription. Historically, the FDA has regulated drug approval through rigorous clinical testing, and the current move raises concerns about circumventing these established protocols. The popularity of peptides has surged in recent years, often fueled by online marketing and anecdotal claims of benefits that lack substantial scientific validation. This situation underscores ongoing debates about drug safety, consumer access, and the regulatory landscape surrounding compounded medications in the United States.
Want More Context? 🔎
